Please assess the completion status of the following clinical trial:

Trial Title: Dose-escalating Safety Study in Subjects on Stable Statin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* On a stable dose of \>/= 40 mg Simvastatin or atorvastatin daily for \>/= 3 months prior to baseline and expected to remain on this dose for the remainder of the study~* LDL-cholesterol between 2.60 and 5.70 mmol/L (100 and 220 mg/dL), inclusive at screening~* Females not of childbearing potential.~Exclusion Criteria:~* History of CHD or CHD-equivalent (such as diabetes mellitus, or another clinical form of atherosclerotic disease, e.g., peripheral arterial disease, abdominal aortic aneurysm, or symptomatic carotid artery disease)~* Fasting triglyceride \>2.26 mmol/L (200 mg/dL) at screening~* Any uncontrolled medical/surgical/psychiatric condition, including conditions that may predispose to secondary hypercholesterolemia~* Current diagnosis or known history of complement deficiency or abnormality~* A positive hepatitis B surface antigen or hepatitis C antibody, or a known positive HIV status~* Current diagnosis or known history of liver disease, or has an ALT \>ULN at screening~* Known history of fibromyalgia, myopathy, myositis, rhabdomyolysis, any unexplained muscle pain, or has a CPK \>ULN at screening~* Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin that has been adequately treated~* The advisability of a subject taking any prescription medication (apart from simvastatin or atorvastatin) within 6 weeks prior to screening should be discussed with the Isis Medical Monitor~* Subject unwilling to discontinue taking alternative/herbal medication for the duration of the study~* History of drug abuse within 2 years of screening~* Subject unwilling to limit alcohol consumption for the duration of the study: male subjects to a maximum of 3 drinks (30 g) per day, and \<12 drinks (120 g) per week; female subjects to a maximum of 2 drinks (20 g) per day, and \<8 drinks (80 g) per week~* Known allergy or hypersensitivity to simvastatin~* Undergoing or has undergone treatment with another investigational drug, biologic agent, or device within 3 months, or 3 half lives, prior to screening, whichever is longer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Loading doses followed by weekly maintenance doses
- Cohort B (Type: EXPERIMENTAL): Loading doses followed by weekly maintenance doses
- Cohort C (Type: EXPERIMENTAL): Loading doses followed by weekly maintenance doses
- Cohort D (Type: EXPERIMENTAL): Loading doses followed by weekly maintenance doses
- Cohort E (Type: EXPERIMENTAL): Loading doses followed by weekly maintenance doses
- Cohort F (Type: EXPERIMENTAL): Loading doses followed by extended weekly maintenance doses
- Cohort G (Type: EXPERIMENTAL): Loading doses followed by extended weekly maintenance doses

Based on this trial design, predict the completion outcome and termination type (if applicable).